COMPARISON OF THE EFFICACY OF TOPICAL PERMETHRIN 5% AND ORAL IVERMECTIN IN PATIENTS WITH PEDICULOSIS
Keywords:
Pediculosis capitis, permethrin, ivermectin, efficacyAbstract
Objective: To compare the efficacy of topical permethrin 5% with oral ivermectin in the treatment of patients diagnosed with pediculosis capitis and also evaluate the side effects, recurrence, patient compliance, and long-term effectiveness of both treatment options.
Study Design: Non Randomized Controlled Trial.
Place and Duration of the Study: Department of Dermatology, Pak Emirates Military Hospital (PEMH) and Combined Military Hospital (CMH), Rawalpindi, Punjab, Pakistan, from November 2025 to April 2026.
Methodology: A total of 62 patients clinically diagnosed with pediculosis capitis were selected and randomly allocated to treatment group A (Topical Permethrin 5%) or group B (Oral Ivermectin) by lottery method. In group A permethrin 5% cream was applied to the scalp and hair, left for 12 hours, and rinsed it out. This was repeated after one week to address any remaining lice or nits. In group B, a single dose of oral ivermectin (200 µg/kg body weight) was administered, with a second dose after 7 days if necessary. Each patient was evaluated for efficacy, reduction in symptoms, side effects, and compliance on days 7, 14, and 28, while recurrence and long-term effectiveness was assessed on day 28.
Results: Of 62 patients, females were 71.0% (n=22) vs. 77.4% (n=24), and males were 29.0% (n=9) vs. 22.6% (n=7) with a median age of 17.0 (12.0-29.0) vs. 15.0 (12.0-26.0) years in the permethrin 5% and ivermectin groups, respectively. On comparison, efficacy was 48.4%, 100%, and 90.3% in the permethrin 5% group and 87.1%, 100%, and 96.8% in the ivermectin group on days 7, 14, and 28, respectively.
Published
Issue
Section
License
Copyright (c) 2026 Dr Sana Suleman, Dr Tehseen Khalid, Dr Muhammad Umer Farooq Anwar, Dr Saira Hassan, Dr Maham Mumtaz, Dr zainab Kazam

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.